Sanofi's isatuximab meets survival endpoint for third-line MM

Sanofi (Euronext:SAN; NASDAQ:SNY) said it will submit regulatory applications to FDA and EMA this half for isatuximab in relapsed or refractory multiple myeloma after the humanized IgG1 mAb against CD38 met the primary endpoint in the Phase III ICARIA-MM trial in the indication.

Sanofi said isatuximab in combination with standard of care -- Pomalyst pomalidomide and dexamethasone -- significantly improved progression-free survival (PFS) vs. SOC alone...